dasatinib

Overview

Dasatinib is a second-generation, orally bioavailable tyrosine kinase inhibitor (TKI) developed primarily for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It exerts its anticancer effects by potently inhibiting BCR-ABL1, the constitutively active fusion kinase that drives CML pathogenesis, as well as a broad spectrum of additional kinases including SRC-family kinases, c-KIT, PDGFR, and ephrin receptors. This multitarget profile distinguishes dasatinib from first-generation TKIs such as imatinib and underpins both its enhanced potency against BCR-ABL1 mutations and its broader applicability across multiple tumor types. Dasatinib binds BCR-ABL1 in both its active and inactive conformations, giving it activity against many imatinib-resistant mutants. Its inhibition of SRC-family kinases is particularly relevant beyond CML, as SRC-mediated compensatory signaling is a recognized resistance mechanism in non-small cell lung cancer and other solid tumors.

Despite its clinical efficacy, dasatinib carries a well-characterized toxicity profile that includes pleural effusions, pulmonary arterial hypertension, and cardiopulmonary complications. Dose optimization has therefore become a central research question in CML management, aiming to preserve therapeutic depth of response while mitigating adverse effects and reducing treatment cost. Emerging evidence also positions dasatinib as a candidate agent in several solid tumor contexts, including triple-negative breast cancer (TNBC) and pediatric diffuse intrinsic pontine glioma (DIPG), reflecting the broad oncological relevance of its kinase inhibition profile.

Focus of Latest Publications

Recent publications collectively illustrate dasatinib's evolving role across both hematologic malignancies and solid tumors, with a growing emphasis on dose individualization, cardiotoxicity monitoring, resistance mechanisms, and novel combination strategies.

Dose Optimization in CML. A prospective cohort study published in Leukemia Research (PMID 41932299) directly addressed dose optimization in CML by comparing a response-adapted dasatinib de-escalation strategy—starting at the standard 100 mg dose and reducing based on treatment response—against an upfront low-dose 50 mg regimen in 143 newly diagnosed chronic-phase CML patients. The study framed dose-optimization as a critical strategy to balance efficacy, safety, and cost, reflecting the clinical reality that many patients on 100 mg experience toxicities that necessitate dose reduction, and that lower doses may achieve comparable molecular responses in a substantial proportion of patients.

Cardiopulmonary Toxicity Assessment. A comprehensive echocardiographic investigation published in Echocardiography (PMID 42206579) systematically characterized the cardiac changes occurring in CML patients receiving dasatinib. Using echocardiographic assessment as the primary technology, the study highlighted that while dasatinib's cardiopulmonary toxicities are established, the specific echocardiographic phenotype associated with this therapy remained poorly characterized. This work adds granularity to the cardiovascular monitoring framework needed for patients on long-term dasatinib treatment.

Activity in Triple-Negative breast cancer. Research published in Cancer Research (PMID 41671401) employed high-throughput machine-learning screening of 3,200 FDA-approved compounds across breast cancer cell lines stratified by basal marker expression. This study identified dasatinib as a promising candidate with selective activity against triple-negative breast cancer (tB-TNBC) models, suggesting that SRC-family and other kinase dependencies in specific TNBC subtypes may render them susceptible to dasatinib. This finding opens a rationale for investigating dasatinib in biomarker-defined TNBC subpopulations.

Drug Transporter Interactions. A pharmacological study in Cancer Chemotherapy and Pharmacology (PMID 42118353) characterized the interactions of various TKIs used in CML—including dasatinib—with P-glycoprotein (P-gp) and breast cancer Resistance Protein (BCRP), two efflux transporters that influence intracellular drug concentrations and resistance. Using in vitro cellular and vesicular transport assays, the study found that dasatinib and bosutinib were less effective as BCRP inhibitors compared to asciminib, imatinib, nilotinib, and ponatinib, with implications for drug-drug interactions and the selection of TKI combinations. This is particularly relevant in contexts where BCRP-mediated efflux might limit dasatinib's intracellular efficacy or alter co-administered drug pharmacokinetics.

Immune Subtyping and Therapeutic Vulnerabilities. A study in uveal melanoma published in Discover Oncology (PMID 42091786) applied a multidimensional immune ecological subtyping framework to identify tumor subtypes with distinct therapeutic sensitivities. Tumors classified as CS1 showed specific sensitivities to dasatinib alongside lapatinib, paclitaxel, and cisplatin, indicating that immune-state-associated molecular programs can predict susceptibility to dasatinib in non-hematologic cancers. This work connects immune activity, intercellular communication, and metabolic programs to differential drug sensitivity, positioning dasatinib within an immune contexture-driven treatment selection paradigm.

Pediatric Brain Tumor Combinations. The randomized phase 2 BIOMEDE trial, published in Nature Medicine (PMID 42032072), evaluated dasatinib's multitarget tyrosine kinase inhibition in combination with radiotherapy in diffuse intrinsic pontine glioma (DIPG), a pediatric brain tumor with extremely poor prognosis. The study compared dasatinib-plus-radiotherapy arms against temozolomide-plus-radiotherapy and everolimus-plus-radiotherapy regimens, reflecting the mechanistic hypothesis that targeting kinase signaling alongside standard radiotherapy could improve outcomes. The involvement of mechanistic target of rapamycin kinase (mTOR) inhibition via everolimus in the comparator arm and the inclusion of temozolomide—a DNA-alkylating agent—underscores the complex, multi-pathway biology of DIPG that these trials sought to exploit.

Synergistic Combinations in NSCLC. A computational study in PLoS ONE (PMID 42118752) analyzed 607 drug combinations in non-small cell lung cancer using metagene-based classification, Graph-regularized Non-negative Matrix Factorization, and Random Walk with Restart algorithms applied to A549 lung epithelial cells. The analysis found that dasatinib synergizes with other agents through co-targeting of SRC-family compensatory pathways, consistent with the known role of SRC kinases in mediating adaptive resistance to diverse oncology therapies. This points toward rational combination strategies pairing dasatinib with drugs targeting upstream or parallel pathways such as PI3K/Akt signaling to overcome resistance mechanisms.

Key Publications

• Jun Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study. (Leukemia research, 2026, PMID 41932299): "Dose-optimization of dasatinib is an important strategy in chronic myeloid leukaemia (CML) to balance efficacy, safety, and cost."
• Jun A Comprehensive Echocardiographic Assessment of Patients With Chronic Myeloid Leukemia on Dasatinib. (Echocardiography (Mount Kisco, N.Y.), 2026, PMID 42206579): "Dasatinib, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), is known to cause cardiopulmonary toxicities; however, little is known about the echocardiographic changes associated with this therapy."
• May Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies. (Cancer research, 2026, PMID 41671401): "High-throughput screening of 3,200 FDA-approved compounds in breast cancer cell lines classified according to basal marker expression identified dasatinib as a promising candidate with selective activity against tB-TNBC models."
• May Uncovering the mechanisms of synergistic drug combinations in non-small cell lung cancer through metagene-based classification. (PloS one, 2026, PMID 42118752): "for instance, synergy with dasatinib appears to result from co-targeting SRC compensatory pathways."
• May Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia. (Cancer chemotherapy and pharmacology, 2026, PMID 42118353): "Conversely, asciminib demonstrated notable potency against BCRP, ranking it among the strong inhibitors imatinib, nilotinib, and ponatinib, while dasatinib and bosutinib were less effective."
• May Multidimensional immune ecological subtyping identifies RUNX1 as a prognostic factor in uveal melanoma. (Discover oncology, 2026, PMID 42091786): "CS1 tumors exhibited distinct sensitivities to dasatinib, lapatinib, paclitaxel, and cisplatin, indicating immune-state-associated therapeutic vulnerabilities."
• Apr Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial. (Nature medicine, 2026, PMID 42032072): "...multitargeted tyrosine kinase inhibitor dasatinib in combination with radiotherapy..."